Faster-Acting Insulins

Slides:

Advertisements

Similar presentations

Diabetes Mellitus.

Advertisements

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Diabetes Control in Youth: The American Experience Georgeanna J. Klingensmith, MD Keystone Colorado July 2008.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Insulin therapy.

GENE THERAPY FOR DIABETES Lindsey Rowbotham Period 7.

EVALUATION OF CONVENTIONAL V. INTENSIVE BLOOD GLUCOSE CONTROL Glycemic Control in Critically Ill Patients DANELLE BLUME UNIVERSITY OF GEORGIA COLLEGE OF.

Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.

Toujeo® and it’s Place in Therapy

Part 10. FPG (mg/dL) BaselineDay 8Day 15 Vehicle (n=6) 0.01 mg/kg (n=6) 0.1 mg/kg (n=6) 1 mg/kg (n=6) 10 mg/kg (n=6) *P

Tresiba- insulin degludec

Insulin Initiation With NovoMix30

Diabetes Update: Michael Gottschalk, M.D, Ph.D.

{ Practicalities of intesive insulin therapy to optimase diabetes control Ewa Pańkowska MD, PhD Warsaw, Poland Warsaw, Poland.

Pattern Recognition Ver D/sv/ What Is Pattern Management ? A systematic approach to making effective use of SMBG data. – Establishing pre-

Date of download: 6/24/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

Dr Ravi Kant Premix Analogue VS. Premix Human Insulin In Clinical Practice.

CAN WE IMPROVE POSTPRANDIAL GLUCOSE CONTROL WITH FAST-ACTING INSULINS?

Achieving Optimal Glycaemic Control: Can Insulin Deliver?

Maximum exogenous insulin concentrations were highest for PO insulin (625360 U), followed by DU (453436 U) and SC (10145.7 U) insulin. Peak absorption.

Key publication slides

Key publication slides

Updates and Perspectives in Diabetic Dyslipidemia

Applying Data to Practice

Making the Case for Metabolic Surgery in Patients With Obesity and T2DM.

Patient Case 1 Peggy Peggy Interactive Case Question.

Faster-Acting Insulins

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

The Next Generation of Basal Insulins

Utilizing New Technologies and Insulins for a Tighter Grip on PPG

Patient Outcomes in Bariatric Surgery: Bridging the Divide to Postoperative Success.

Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.

Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.

Novel Concentrated Insulins: What Benefits and for Which Patients?

Diabetes Journal Club Julie Shah.

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

GLP-1 Receptor Agonists: How Early Is Appropriate?

When Would You Use Single Inhaler Triple Therapy in COPD?

Pramlintide Synthetic analog of the β-cell hormone amylin

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

Novel Approaches to T1D Management

T2DM Management.

Better Diabetes Control With Novel Basal Insulins

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Approach to starting and adjusting insulin in type 2 diabetes.

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Dual SGLT1/SGLT2 Inhibition in T1D

Key Insulin Side Effects*

Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Glucose Management and Statin Therapy

Proteasome Inhibitors and Patients

Guidelines for Initiation of Therapy

Are All Novel Insulins Proven to Be Equally Safe?

Glucose Management and Statin Therapy

Pramlintide Therapy Part 1of 2

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Fig. 3. (A) Least-squares (LS) mean difference in glycosylated hemoglobin (HbA1c) from baseline, and (B) LS mean difference in HbA1c from baseline over.

Statin Therapy in Patients With Insulin Resistance

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Fresh perspectives ON BASAL Insulins in diabetes care

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Presentation transcript:

Faster-Acting Insulins

Program Overview

Impact of Postprandial Hyperglycemia

Major Mechanisms Linking Elevated PPG to Diabetes Complications

Recommended Targets for PPG

Insulin Replacement Therapy Aims to Recreate the Normal Blood Insulin Profile

PK Profiles of Insulin Replacement Therapies

Faster-Acting Insulin: Approaching a More Exact Physiologic Insulin Profile

Effects of Hormone Signaling on Hepatic Glucose Metabolism

Faster Aspart: A New Formulation of Insulin Aspart

Faster Aspart vs Insulin Aspart via SC Injection: PK/PD Comparisons*

PK/PD Differences of Faster Aspart With CSII Are Even More Pronounced Than With SC Injections

PD Differences Between Faster Aspart and Insulin Aspart of Similar Magnitude Compared With Differences Between Insulin Aspart and RHI

Onset® Program for Faster Aspart

Onset® 1: Study Design

Onset® 1: Mean HbA1c Change From Baseline

Onset® 1: PPG Increment at Week 26

Onset® 1: Safety

Timing of Administration of Faster Aspart

Timing of Meal Insulin and Its Relation to Adherence to Therapy in T1DM

Practical Recommendations Regarding Timing of Administration

Other Faster-Acting Insulins in Development

Onset, Offset, and Overall Exposure of Faster Aspart vs Insulin Aspart in CSII

Onset® 4: A Trial Evaluating Compatibility and Safety of Faster Aspart and Insulin Aspart With an External CSII System in Adults With T1DM

Patients With T1DM Who May Be Candidates for Faster Aspart

24-Year-Old Woman With T1DM

Onset® 2: Study Design

Onset® 2*: Mean Change in HbA1c Over Time

Onset® 2: PPG Increment (Meal Test) at Week 26

Onset® 2: Treatment-Emergent Hypoglycemia

Other Faster-Acting Insulins in Development (cont)

Patients With T2DM Who May Be Candidates for Faster Aspart

58-Year-Old Man With T2DM for 8 Years

58-Year-Old Man With T2DM for 8 Years (cont)

58-Year-Old Man With T2DM for 8 Years (cont)

58-Year-Old Man With T2DM for 8 Years (cont)

58-Year-Old Man With T2DM for 8 Years (cont)

60-Year-Old Woman With T2DM for 15 Years

60-Year-Old Woman With T2DM for 15 Years (cont)

60-Year-Old Woman With T2DM for 15 Years (cont)

60-Year-Old Woman With T2DM for 15 Years (cont)

60-Year-Old Woman With T2DM for 15 Years (cont)

Conclusions

Conclusions (cont)